Cemdisiran
Product Sizes
1 mg
£ POA
HY-145720-1MG
25 mg
£ POA
HY-145720-25MG
10 mg
£ POA
HY-145720-10MG
5 mg
£ POA
HY-145720-5MG
About this Product
- SKU:
- HY-145720
- Additional Names:
- ALN-CC5
- CAS Number:
- 1639264-46-2
- Extra Details:
- Cemdisiran (ALN-CC5) is an N-acetylgalactosamine-conjugated RNAi agent and also a complement component C5 inhibitor. Cemdisiran targets C5 mRNA; cleaves C5 mRNA via the endogenous RNA interference pathway; and inhibits the production of C5 protein in the liver. Cemdisiran exerts a dose-dependent inhibitory effect on total C5 concentrations in cynomolgus monkeys. When used in combination with Pozelimab (HY-P99786) in cynomolgus monkeys; Cemdisiran achieves a more sustained and complete inhibitory effect on complement activity. Cemdisiran can be used in the research of paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases[1][2].
- Molecular Weight:
- 16782.53
- Purity:
- 95.24
- References:
- [1]Badri P, Jiang X, Borodovsky A, et al. Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria. Clin Pharmacokinet. 2021;60(3):365-378.|[2]Prajakta Badri, et al. Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria. Clin Pharmacokinet. 2021;60(3):365-378.
- Research Area:
- Metabolic Disease
- Shipping Conditions:
- Ambient
- Storage Conditions:
- 4[o]C (Powder; sealed storage; away from moisture)
- Type:
- Molecular Biology Reagents: Nucleic Acids
- Pathway:
- Epigenetics;Immunology/Inflammation
